Get started
Work

653O Pembrolizumab (pembro) vs placebo as adjuvant therapy for patients (pts) with renal cell carcinoma (RCC): Patient-reported outcomes (PRO) in KEYNOTE-564

Year: 2021
Type: article
DOI: 10.1016/j.annonc.2021.08.049
Authors: T.K. Choueiri, P. Tomczak, S.H. Park, B. Venugopal, S. Symeonides, J. Hajek, T. Ferguson, Y-H. Chang, J.L. Lee, N. Haas, P. Sawrycki, N. Sarwar, M. Gross-Goupil, A. Thiery-Vuillemin, M. Mahave, T.L. Saretsky, P. Zhang, J. Willemann-Rogerio, D.I. Quinn, T.B. Powles
Institutions: Dana-Farber Cancer Institute, Poznan University of Medical Sciences, Samsung Medical Center, Sungkyunkwan University, Beatson West of Scotland Cancer Centre, University of Glasgow, Edinburgh Cancer Research, University of Edinburgh, University Hospital Ostrava, Fiona Stanley Hospital, Taipei Veterans General Hospital, Asan Medical Center, University of Ulsan, Abramson Cancer Center, Provincial Polyclinical Hospital in Toruń, Imperial College Healthcare NHS Trust, Centre Hospitalier Universitaire de Bordeaux, Hôpital Saint-André, Centre Hospitalier Universitaire de Besançon, Fundación Arturo López Pérez, Merck & Co., Inc., Rahway, NJ, USA (United States), University of Southern California, USC Norris Comprehensive Cancer Center, The Royal Free Hospital, University College London
Language: English
Field: Medicine
Open Access status: bronze
OpenAlex ID: W3203334883
FWCI: 0.424
Cites:
Cited by: 4
Related to: 10